CUA Educational Content

Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients
with Urological Cancers – Adverse Events (AEs) Management Tool Kit

PRINTABLE VERSIONS AVAILABLE.

 

CUA Members: Log in to access printable versions and to download the tools directly to your preferred device.

All CUA educational materials have undergone an official approval process and are the intellectual property of the Canadian Urological Association (CUA). Reproduction of these documents in any form requires the express written consent of the CUA. For any permission requests, comments/feedback, or to enquire about program content, please contact: rita.demarco@cua.org. 

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy